Comparing United Therapeutics (NASDAQ:UTHR) & Bolt Biotherapeutics (NASDAQ:BOLT)

United Therapeutics (NASDAQ:UTHR) and Bolt Biotherapeutics (NASDAQ:BOLT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Insider & Institutional Ownership

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

United Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Valuation and Earnings

This table compares United Therapeutics and Bolt Biotherapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18 billion	7.46	$1.33 billion	$27.95	19.82
Bolt Biotherapeutics	$7.70 million	1.08	-$33.38 million	($16.44)	-0.26

United Therapeutics has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares United Therapeutics and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Analyst Recommendations

This is a breakdown of current ratings and price targets for United Therapeutics and Bolt Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1	2	12	0	2.73
Bolt Biotherapeutics	1	1	2	0	2.25

United Therapeutics currently has a consensus price target of $651.21, suggesting a potential upside of 17.57%. Bolt Biotherapeutics has a consensus price target of $14.50, suggesting a potential upside of 236.43%. Given Bolt Biotherapeutics’ higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than United Therapeutics.

Summary

United Therapeutics beats Bolt Biotherapeutics on 11 of the 14 factors compared between the two stocks.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.